Meeting
2022 ASCO Annual Meeting
Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
Authors
Christine Megerdichian Parseghian
The University of Texas MD Anderson Cancer Center, Houston, TX
Christine Megerdichian Parseghian , Eduardo Vilar Sanchez , Ryan Sun , Madhulika Eluri , Van K. Morris II, Benny Johnson , Maria Pia Morelli , Michael J. Overman , Jason Willis , Ryan Huey , Kanwal Pratap Singh Raghav , Arvind Dasari , Bryan K. Kee , Robert A. Wolff , John Paul Y.C. Shen , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03087071
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3520)
DOI
10.1200/JCO.2022.40.16_suppl.3520
Abstract #
3520
Poster Bd #
314
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
First Author: Xiaojing Xu
Poster
2022 ASCO Annual Meeting
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.
First Author: Xiaojing Xu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely